Top-News
Pharmazeutika USA

Ultragenyx Pharmeutical Inc News

Aktie
WKN:  A1XCY0 ISIN:  US90400D1081 US-Symbol:  RARE
40,00 €
-0,40 €
-0,99%
03.05.24 14:16:59
Handeln Depot/Watchlist
Aktienanzahl *
82,34 Mio.
Marktkapitalisierung *
3,33 Mrd. €
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 24.04.2024

Ultragenyx Pharmeutical Inc News

04.01.24 - GlobeNewswire
Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza® ▼ (evinacumab) for Adolescents and Adults Aged 12 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)
NOVATO, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the National Institute for Health and Care Excellence ...
18.12.23 - GlobeNewswire
Ultragenyx Receives European Commission Decision for Evkeeza® (evinacumab) Expanded Indication in Children Aged 5 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)
For the first time, paediatric patients aged 5-11 years with HoFH in the EU have access to a first-​in-class medicine to treat an ultrarare, inherited form of high cholesterol
18.09.23 - Wikifolio
Die heißesten Aktien der letzten Woche
Hier erfährst du, welche Aktien letzte Woche besonders oft ge- oder verkauft wurden und welche Motive dafür entscheidend waren.
01.09.23 - GlobeNewswire
Zur Behandlung der homozygoten familiären Hypercholesterinämie (HoFH): Ultragenyx führt Evkeeza® (Evinacumab) in Deutschland ein
Evkeeza® ist das erste von der U.S. Food and Drug Administration (FDA) und der Europäischen Kommission (EC) zugelassene Medikament einer neuen Klasse zur Behandlung ...
29.08.23 - PR Newswire
TSX Venture Exchange Stock Maintenance Bulletins
TSX Venture Exchange Stock Maintenance Bulletins Canada NewsWire
09.09.21 - GlobeNewswire
MEDIA ADVISORY: Ultragenyx Announces Mepsevii® (vestronidase alfa) Receives Reimbursement Approval for Treatment of Mucopolysaccharidosis VII in Italy
NOVATO, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development and commercialization of novel ...
13.07.21 - GlobeNewswire
MEDIA ADVISORY: Ultragenyx Announces Mepsevii® (vestronidase alfa) Receives Reimbursement Approval for Treatment of Mucopolysaccharidosis VII in Spain
MADRID, Spain, July 13, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development and commercialization of novel ...
31.03.20 - PR Newswire
REGENXBIO and Ultragenyx Announce New License Agreement for Use of NAV® Technology Platform for the Treatment of Rare Metabolic Disorder
REGENXBIO and Ultragenyx Announce New License Agreement for Use of NAV® Technology Platform for the Treatment of Rare Metabolic Disorder - REGENXBIO grants Ultragenyx ...
15.01.20 - PR Newswire
Thinking about buying stock in Bank of America, Nio, Ultragenyx Pharmaceutical, Tilray, or Walmart?
Thinking about buying stock in Bank of America, Nio, Ultragenyx Pharmaceutical, Tilray, or Walmart? PR Newswire
17.05.18 - PR Newswire
Ultragenyx and Kyowa Kirin Announce Topline Phase 3 Study Results Demonstrating Superiority of Crysvita® (burosumab) Treatment to Oral Phosphate and Active Vitamin D in Children with X-Linked Hypophos
Ultragenyx and Kyowa Kirin Announce Topline Phase 3 Study Results Demonstrating Superiority of Crysvita® (burosumab) Treatment to Oral Phosphate and Active Vitamin D in ...
23.02.18 - PR Newswire
Kyowa Kirin und Ultragenyx geben bekannt, dass Crysvita® (Burosumab) eine bedingte Zulassung in Europa zur Behandlung der X-chromosomalen Hypophosphatämie erhält
Kyowa Kirin und Ultragenyx geben bekannt, dass Crysvita® (Burosumab) eine bedingte Zulassung in Europa zur Behandlung der X-​chromosomalen Hypophosphatämie erhält PR ...
23.02.18 - PR Newswire
Kyowa Kirin and Ultragenyx Announce Crysvita® (burosumab) Receives Conditional Marketing Authorisation in Europe for the Treatment of X-Linked Hypophosphatemia in Children
Kyowa Kirin and Ultragenyx Announce Crysvita® (burosumab) Receives Conditional Marketing Authorisation in Europe for the Treatment of X-Linked Hypophosphatemia in Children ...
23.02.18 - PR Newswire
Kyowa Kirin and Ultragenyx Announce Crysvita® (burosumab) Receives Conditional Marketing Authorisation in Europe for the Treatment of X-Linked Hypophosphatemia in Children
Kyowa Kirin and Ultragenyx Announce Crysvita® (burosumab) Receives Conditional Marketing Authorisation in Europe for the Treatment of X-Linked Hypophosphatemia in Children ...
15.11.17 - PR Newswire
Thinking about buying Acorda Therapeutics, JA Solar, Ultragenyx Pharmaceuticals, Square Inc. or Target?
Thinking about buying Acorda Therapeutics, JA Solar, Ultragenyx Pharmaceuticals, Square Inc. or Target? PR Newswire
13.10.17 - PR Newswire
WEISSLAW LLP: Dimension Therapeutics, Inc. Acquisition May Not Be in the Best Interests of DMTX Shareholders
WEISSLAW LLP: Dimension Therapeutics, Inc. Acquisition May Not Be in the Best Interests of DMTX Shareholders PR Newswire
03.03.17 - PR Newswire
PriceWatch Alert: High return covered-call trades for Cliffs Natural Resources, JD.com, Realty Income, Ultragenyx Pharmaceuticals and YY
PriceWatch Alert: High return covered-​call trades for Cliffs Natural Resources, JD.com, Realty Income, Ultragenyx Pharmaceuticals and YY PR Newswire
28.10.16 - PR Newswire
Covered Call reports for CenturyLink, Francesca's Holdings Company, Myriad Genetics, Stamps.Com Inc. and Ultragenyx Pharmaceuticals include trade ideas that offer returns of 19% or more!
Covered Call reports for CenturyLink, Francesca's Holdings Company, Myriad Genetics, Stamps.Com Inc. and Ultragenyx Pharmaceuticals include trade ideas that offer returns of ...

Newssuche

Videos

newspaper
03.05.24 -13,45%
Technical Trading: Gold freitags Long
Gold Long Typ: Turbo Open End WKN: NG8DB8 Hebel: 27 Laufzeit: OpenEnd Einstieg: Market ... Mehr »